Learn how SAMHSA’s Division of Pharmacologic Therapies (DPT) works to oversee medication-assisted treatment (MAT) for substance use disorders. The Division of Pharmacologic Therapies (DPT), part of SAMHSA’s Center for Substance Abuse Treatment (CSAT) manages the day-to-day oversight activities necessary to implement federal regulations on the use of substance use disorder medications such as methadone and buprenorphine for the treatment of opioid use disorder (OUD). DPT supports the certification and accreditation of more than 1,700 opioid treatment programs (OTPs) that collectively treat more than 300,000 patients each year. Learn more about SAMHSA’s certification and accreditation of OTPs and oversight of OTP Accrediting Bodies. DPT also implements the Drug Addiction Treatment Act of 2000 (DATA 2000) and Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act). These laws expand the clinical context of medication-assisted treatment (MAT) by allowing qualified practitioners to dispense or prescribe medications for the treatment of OUD in settings other than OTPs and other facilities. Learn about the different medications and counseling used in MAT approved by the Food and Drug Administration (FDA) to treat substance use disorders. Find information on buprenorphine waiver training or SAMHSA training and resources. Learn more about the statues, regulations, and guidelines that govern MAT. Contact SAMHSA’s OTP Compliance Officers.